论文部分内容阅读
目的:探讨对肥胖2型糖尿病合并H型高血压患者实施利拉鲁肽治疗的方法和临床效果。方法:选取2015年4月至2016年4月我院收治的肥胖2型糖尿病合并H型高血压患者60例,将其随机分为两组,对照组患者实施二甲双胍肠溶片治疗,观察组患者实施利拉鲁肽联合二甲双胍治疗,观察两组患者在治疗后身体各指标改变情况。结果:观察组患者在空腹血糖、血压等指标均的检查结果上均显著优于对照组,P<0.05,有统计学意义。结论:对肥胖2型糖尿病合并H型高血压患者实施利拉鲁肽治疗的疗效显著,值得临床进行推广。
Objective: To explore the method and clinical effect of liraglutide in obese type 2 diabetic patients with Hypertension. Methods: From April 2015 to April 2016, 60 patients with obese type 2 diabetes mellitus and Hypertension admitted to our hospital were randomly divided into two groups. Patients in the control group were treated with metformin enteric-coated tablets. Patients in the observation group The implementation of liraglutide combined with metformin treatment, observation of two groups of patients after treatment, the body changes in the indicators. Results: In the observation group, the results of fasting blood glucose, blood pressure and other indicators were significantly better than the control group, P <0.05, with statistical significance. Conclusion: The effect of liraglutide on obese type 2 diabetes mellitus patients with Hypertension is significant and worthy of clinical promotion.